Amgen collaborating with Adaptive to create COVID-19 medicine
Thousand Oaks-based biotech giant Amgen announced April 2 that it is collaborating with Adaptive Biotechnologies to discover and develop antibodies that can be used to prevent or treat COVID-19. Amgen shares gained 4 percent to $205.88 as of 10:25 a.m and Adaptive’s stock was up 0.8 percent to $27.72. Year-to-date, Amgen’s stock is down 14 Read More →
Thousand Oaks biotech Amgen ponders acquisitions
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Dubroff: Boeing taps Amgen’s Bradway to navigate 737 MAX mess
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Judge rules for Amgen in patent dispute over Repatha competitor
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen Foundation donating $21 million to scholars program
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
New drugs boost profits at Amgen as two executives leave company
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen revenues fall but profits increase
Thousand Oaks-based biotech giant Amgen’s total revenues decreased by 1 percent to $5.5 billion during the first quarter of 2017, compared to the same period a year ago, according to an earnings report April 26. The drop was related to the plunge in sales of Enbrel, its rheumatoid arthritis drug. Sales decreased 15 percent due Read More →
